Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cartitone
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cartitone (also marketed as Carti-Tone) is an oral fixed-dose combination tablet developed and manufactured by Anglo-French Drugs & Industries for the management of osteoarthritis and joint pain. The formulation contains three active ingredients: diacerein (50 mg), glucosamine (750 mg), and methylsulfonylmethane (MSM) (250 mg). Diacerein acts as an anti-inflammatory agent by inhibiting interleukin-1 beta (IL-1β) production and signaling, which prevents cartilage degradation. Glucosamine serves as a precursor for glycosaminoglycan and proteoglycan synthesis, supporting cartilage repair and reducing inflammatory cytokine expression. Methylsulfonylmethane (MSM) provides organic sulfur to support joint tissue structure and exerts anti-inflammatory and antioxidant effects by modulating NF-κB and NLRP3 inflammasome pathways. Together, these components work synergistically to reduce joint friction, alleviate pain and swelling, and improve physical mobility in patients with degenerative joint diseases.
- Brand names
- Carti-ToneCartitone
- Other names
- diacerein + glucosamine + methylsulfonylmethane
02
Targets
IL1B (Interleukin-1 beta)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)RELA (Nuclear Factor Kappa B Subunit p65)
Beyond the preview
Go deeper on Cartitone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cartitone.